title: Phase II study on mitoxantrone in adenoid cystic carcinomas of the head and neck. EORTC Head and Neck Cancer Cooperative Group.
abstract: BACKGROUND
  Based on activity in a case report, mitoxantrone was studied in a phase II study in adenoid cystic carcinoma.
  
  
  METHODS
  Patients with symptomatic and/or rapidly progressive metastatic or recurrent adenoid cystic carcinoma were eligible for this study. They were treated with mitoxantrone given intravenously by bolus injection at a dose of 14 mg/m2, cycles repeated every 3 weeks.
  
  
  RESULTS
  Thirty-six chemotherapy-naive patients entered on trial, 4 were ineligible. A median of 6 cycles per patient were given. Leucocytopenia (in 97% of patients) was the most important side effect and tended to be cumulative. Other side effects were mainly mild to moderate and consisted of nausea (62%), vomiting (29%), alopecia (53%) and mucositis (41%). Four of 32 patients had a partial response (12%; 95% CI 4%-29%) lasting 3-13 months, 22 patients (69%) had a stable disease.
  
  
  CONCLUSIONS
  Mitoxantrone at this dose and schedule has modest activity in adenoid cystic carcinomas.
authors.affiliation: Department of Medical Oncology, Rotterdam Cancer Institute (Daniel den Hoed Kliniek), The Netherlands.
authors.forename: J
authors.initials: J
authors.lastname: Verweij
authors.forename: P H
authors.initials: PH
authors.lastname: de Mulder
authors.forename: A
authors.initials: A
authors.lastname: de Graeff
authors.forename: J B
authors.initials: JB
authors.lastname: Vermorken
authors.forename: J
authors.initials: J
authors.lastname: Wildiers
authors.forename: J
authors.initials: J
authors.lastname: Kerger
authors.forename: J
authors.initials: J
authors.lastname: Schornagel
authors.forename: F
authors.initials: F
authors.lastname: Cognetti
authors.forename: A
authors.initials: A
authors.lastname: Kirkpatrick
authors.forename: T
authors.initials: T
authors.lastname: Sahmoud
authors.forename: J L
authors.initials: JL
authors.lastname: Lefebvre
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003528:Carcinoma, Adenoid Cystic / Q000175:diagnosis / Q000188:drug therapy*; D016001:Confidence Intervals; D018572:Disease-Free Survival; D004305:Dose-Response Relationship, Drug; D005260:Female; D006258:Head and Neck Neoplasms / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011379:Prognosis
chemical_list: D000970:Antineoplastic Agents; D008942:Mitoxantrone